Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].

Bulletin du cancer - 1 May 2021

Sibaud Vincent, Baric Lilian, Cantagrel Alain, Di Palma Mario, Ederhy Stéphane, Paques Michel, Perlemuter Gabriel

Abstract excerpt

Major therapeutic advances have been made recently in the treatment of metastatic melanoma, due to the development of targeted therapies, namely BRAF and MEK inhibitors, in patients with BRAF V600 mutation. Combinations of vemurafenib+cobimetinib, dabrafenib+trametinib, et encorafenib+binimetinib, evaluated in coBRIM, COMBI-d/COMBI-v and COLUMBUS trials respectively have been approved in this indication....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Carbamates
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Piperidines

Share to Pyridones

Share to Pyrimidinones

Share to Vemurafenib

Source

Identifiers

PMID: 33812673
DOI: 10.1016/j.bulcan.2020.12.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].PMID 33812673Read ↗

[Treatment combinations in BRAF-mutant metastatic melanoma.]Semantic proximity Read ↗

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.